AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10450777 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no ergonomic training)
Number of subjects: 627
Study 7847966 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia (group A)
Number of subjects: 30
Study 7847966 — intervention group
Group type: COMPARATOR
Intervention: Combined antegrade/retrograde cardioplegia (group A/R)
Number of subjects: 30
Study 7847966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 2278370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with tramadol: loading dose 3 mg/kg, demand dose 30 mg, lock‐out time 5 min, concurrent infusion 5 mg/h
Number of subjects: 20
Study 2278370 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) with tramadol: loading dose 3 mg/kg, continuous infusion 0.35 mg/kg per h
Number of subjects: 20
Study 2278370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCA and CI with tramadol
Number of subjects: 20
Study 87315 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse brain stimulation (DBS) administered just before sleep onset
Number of subjects: 7
Study 31896036 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 784
Study 31896036 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 784
Study 31896036 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior GIB (both Apixaban and Warfarin)
Number of subjects: 784
Study 31896036 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior GIB <1 year before randomization (both Apixaban and Warfarin)
Number of subjects: 784
Study 31896036 — intervention group
Group type: COMPARATOR
Intervention: Apixaban vs. Warfarin
Number of subjects: 784
Study 30852244 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHIEVE behavioural weight loss intervention
Number of subjects: 0
Study 28493742 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target BrAC = .08g%)
Number of subjects: 162
Study 28493742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 28493742 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk gamblers (n = 41)
Number of subjects: 162
Study 25822241 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution Modification Training (AMT)
Number of subjects: 85
Study 25822241 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 85
Study 23318051 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (single morning dose)
Number of subjects: 12
Study 23318051 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 12
Study 23318051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23318051 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide and Physical exercise
Number of subjects: 12
Study 23318051 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 12
Study 21109365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 65 mg
Number of subjects: 11
Study 21109365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 100 mg
Number of subjects: 11
Study 21109365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 150 mg
Number of subjects: 11
Study 21109365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 20001132 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood in intentional memorizing condition
Number of subjects: 50
Study 20001132 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood in intentional memorizing condition
Number of subjects: 50
Study 20001132 — intervention group
Group type: COMPARATOR
Intervention: Incidental memorizing condition (both moods)
Number of subjects: 50
Study 17304396 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-fed group (250 ml clear fruit juice 30 minutes postoperatively, unlimited solid food thereafter)
Number of subjects: 196
Study 17304396 — intervention group
Group type: COMPARATOR
Intervention: Control group (clear feeds allowed after two hours, advanced to solids as tolerated)
Number of subjects: 196
Study 17304396 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-fed group
Number of subjects: 196
Study 14574084 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol
Number of subjects: 273
Study 14574084 — intervention group
Group type: COMPARATOR
Intervention: 5 mg bisoprolol
Number of subjects: 273
Study 14574084 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol
Number of subjects: 273
Study 14574084 — intervention group
Group type: COMPARATOR
Intervention: bisoprolol
Number of subjects: 273
Study 10792116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg t.d.s.
Number of subjects: 0
Study 10792116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg t.d.s.
Number of subjects: 0
Study 10792116 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg t.d.s.
Number of subjects: 0
Study 10792116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg t.d.s.
Number of subjects: 0
Study 8675093 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g daily for 9 months)
Number of subjects: 48
Study 8675093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8675093 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 48
Study 8675093 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation and placebo
Number of subjects: 48
Study 1378144 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg p.o.
Number of subjects: 8
Study 1378144 — intervention group
Group type: COMPARATOR
Intervention: Prazosin 2 mg p.o.
Number of subjects: 8
Study 6731562 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted bilateral sanding
Number of subjects: 9
Study 6731562 — intervention group
Group type: EXPERIMENTAL
Intervention: Unresisted bilateral sanding
Number of subjects: 9
Study 2416958 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine
Number of subjects: 8
Study 2416958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29264786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal drug injection (levobupivacaine 150 mg, ketorolac 30 mg, morphine 5 mg)
Number of subjects: 64
Study 29264786 — intervention group
Group type: COMPARATOR
Intervention: Single anesthetic drug injection (levobupivacaine 150 mg)
Number of subjects: 64
Study 27214383 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 300 mg loading dose 12 hours before procedure
Number of subjects: 100
Study 27214383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CoQ10)
Number of subjects: 100
Study 24656645 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC (Bone Marrow Mononuclear Cell) transplantation
Number of subjects: 104
Study 24656645 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle injection)
Number of subjects: 104
Study 22331951 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 503
Study 22331951 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 503
Study 22331951 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to second AI (after washout period)
Number of subjects: 503
Study 22331951 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AI therapy
Number of subjects: 503
Study 22331951 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age and taxane-based chemotherapy
Number of subjects: 503
Study 20819882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy (treated group)
Number of subjects: 24
Study 20819882 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 24
Study 18923577 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct knowledge of carbohydrate intake
Number of subjects: 11
Study 18923577 — intervention group
Group type: COMPARATOR
Intervention: False knowledge of carbohydrate intake (placebo)
Number of subjects: 11
Study 15975732 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) system
Number of subjects: 182
Study 15975732 — intervention group
Group type: COMPARATOR
Intervention: Timeline Followback (TLFB)
Number of subjects: 182
Study 14501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate (ATP) 10 i.v. 30-hour infusions every 2-4 weeks over a 24-week period (n = 28)
Number of subjects: 58
Study 14501386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ATP, n = 30)
Number of subjects: 58
Study 14501386 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate (ATP) in weight-losing patients with stage IIIB NSCLC
Number of subjects: 58
Study 14501386 — intervention group
Group type: COMPARATOR
Intervention: Control group in weight-losing patients with stage IIIB NSCLC
Number of subjects: 58
Study 10825790 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol alone
Number of subjects: 40
Study 10825790 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol with ipratropium bromide
Number of subjects: 40
Study 8875972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg
Number of subjects: 137
Study 8875972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 137
Study 8875972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 137
Study 2059002 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer network support for caregivers; details on dosage and duration not available.
Number of subjects: 0
Study 6650699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (45-90 mg/day)
Number of subjects: 8
Study 6650699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30146405 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerator-stable VARIVAX (8000 PFU)
Number of subjects: 958
Study 30146405 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerator-stable VARIVAX (25000 PFU)
Number of subjects: 958
Study 30146405 — intervention group
Group type: COMPARATOR
Intervention: Frozen VARIVAX (10,000 PFU)
Number of subjects: 958
Study 30146405 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerator-stable VARIVAX with M-M-RII
Number of subjects: 958
Study 30146405 — intervention group
Group type: COMPARATOR
Intervention: Frozen VARIVAX with M-M-RII
Number of subjects: 958
Study 29564844 — intervention group
Group type: EXPERIMENTAL
Intervention: 9x20-sec level strides (105%vVO2max; 1% gradient) with 60 s of recovery
Number of subjects: 11
Study 29564844 — intervention group
Group type: EXPERIMENTAL
Intervention: 6x6-sec uphill strides (105%vVO2max; 5% gradient) with 60 s of recovery
Number of subjects: 11
Study 29564844 — intervention group
Group type: COMPARATOR
Intervention: 7 min at 60%vVO2max as control condition
Number of subjects: 11
Study 29564844 — intervention group
Group type: EXPERIMENTAL
Intervention: All WU conditions
Number of subjects: 11
Study 29564844 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill and level WUs
Number of subjects: 11
Study 29564844 — intervention group
Group type: COMPARATOR
Intervention: Control WUs
Number of subjects: 11
Study 29564844 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity WUs
Number of subjects: 11
Study 26758377 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 2834
Study 26758377 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 2834
Study 24661819 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with others
Number of subjects: 2374
Study 24661819 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants enrolled in the United States/Canada
Number of subjects: 2374
Study 24661819 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking more (7+) prescription medications
Number of subjects: 2374
Study 24661819 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring lower on the Stroke Specific Quality of Life scale
Number of subjects: 2374
Study 24661819 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking fewer (0-2) medications
Number of subjects: 2374
Study 22658437 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) light box emitting 10,000 lx
Number of subjects: 101
Study 22658437 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity (LI) light box emitting 2000 lx
Number of subjects: 101
Study 20206429 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg oxaprozin
Number of subjects: 30
Study 20206429 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium
Number of subjects: 30
Study 20206429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18283734 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon tablets 4000 IU
Number of subjects: 0
Study 16275250 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cryopreservation method
Number of subjects: 201
Study 16275250 — intervention group
Group type: COMPARATOR
Intervention: Standard cryopreservation method
Number of subjects: 201
Study 12078365 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision support tool for stroke prevention in AF
Number of subjects: 0
Study 12078365 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and testing phase for GPs and practice nurses
Number of subjects: 0
Study 9885387 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa benzeraside 2 mg/kg 3 times per day for 1 week
Number of subjects: 32
Study 9885387 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 9885387 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa benzeraside
Number of subjects: 32
Study 9081359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg/day up to 400 mg/day)
Number of subjects: 112
Study 9081359 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (0.8 mg/kg/day)
Number of subjects: 112
Study 9081359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 112
Study 9081359 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 112
Study 1516345 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 350
Number of subjects: 98
Study 1516345 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol 340
Number of subjects: 98
Study 6746962 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained thought
Number of subjects: 20
Study 6746962 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconstrained thought
Number of subjects: 20
Study 31469703 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive technique
Number of subjects: 13
Study 31469703 — intervention group
Group type: COMPARATOR
Intervention: Drip technique
Number of subjects: 13
Study 31469703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 13
Study 29061746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible-tablet formulation of dihydroartemisinin/piperaquine phosphate (DHA/PQP)
Number of subjects: 300
Study 29061746 — intervention group
Group type: COMPARATOR
Intervention: Crushed tablets (Eurartesim)
Number of subjects: 300
Study 27092397 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support and mindfulness program
Number of subjects: 275
Study 27092397 — intervention group
Group type: COMPARATOR
Intervention: Existing mental health resources (control)
Number of subjects: 275
Study 24845800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccination
Number of subjects: 121982
Study 24845800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121982
Study 22555225 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0
Study 21054881 — intervention group
Group type: EXPERIMENTAL
Intervention: Austrian disease management programme (DMP) for diabetes mellitus type 2
Number of subjects: 1489
Study 18303130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience (MS)
Number of subjects: 0
Study 16003858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 2000
Study 16003858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 12438897 — intervention group
Group type: COMPARATOR
Intervention: Tampon sampling for 10 seconds
Number of subjects: 309
Study 12438897 — intervention group
Group type: COMPARATOR
Intervention: Tampon sampling for 1 hour
Number of subjects: 309
Study 12438897 — intervention group
Group type: COMPARATOR
Intervention: Tampon sampling for 4 hours
Number of subjects: 309
Study 12438897 — intervention group
Group type: COMPARATOR
Intervention: Tampon sampling overnight
Number of subjects: 309
Study 12438897 — intervention group
Group type: COMPARATOR
Intervention: Swab sampling
Number of subjects: 309
Study 10435261 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach and Relapse Prevention
Number of subjects: 166
Study 8829715 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family management (BFM)
Number of subjects: 40
Study 8829715 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 40
Study 8829715 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 40
Study 2113671 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (given at ages 1 and 3 months)
Number of subjects: 141
Study 2113671 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (given at ages 2 and 4 months)
Number of subjects: 141
Study 498916 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 0
Study 498916 — intervention group
Group type: COMPARATOR
Intervention: Sodium methylglucamine diatrizoate (10:66)
Number of subjects: 0
Study 498916 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide and Sodium methylglucamine diatrizoate
Number of subjects: 0
Study 31484659 — intervention group
Group type: EXPERIMENTAL
Intervention: 9cUAB30 (n = 8)
Number of subjects: 53
Study 31484659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 2)
Number of subjects: 53
Study 31484659 — intervention group
Group type: EXPERIMENTAL
Intervention: 9cUAB30 (20 mg dose level)
Number of subjects: 53
Study 31484659 — intervention group
Group type: EXPERIMENTAL
Intervention: 9cUAB30 (240 mg dose level)
Number of subjects: 53
Study 31484659 — intervention group
Group type: EXPERIMENTAL
Intervention: 9cUAB30
Number of subjects: 53
Study 29250974 — intervention group
Group type: EXPERIMENTAL
Intervention: Moistened misoprostol (200 µl distilled water, 2 × 200 μg)
Number of subjects: 46
Study 29250974 — intervention group
Group type: COMPARATOR
Intervention: Dry misoprostol (2 × 200 μg)
Number of subjects: 46
Study 29250974 — intervention group
Group type: EXPERIMENTAL
Intervention: Moistened misoprostol
Number of subjects: 46
Study 29250974 — intervention group
Group type: COMPARATOR
Intervention: Dry misoprostol
Number of subjects: 46
Study 29250974 — intervention group
Group type: EXPERIMENTAL
Intervention: Moistened and dry misoprostol
Number of subjects: 46
Study 26271371 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/EE
Number of subjects: 50
Study 26271371 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/E2
Number of subjects: 50
Study 26271371 — intervention group
Group type: COMPARATOR
Intervention: DRSP/EE and KTZ
Number of subjects: 50
Study 26271371 — intervention group
Group type: COMPARATOR
Intervention: DRSP/E2 and KTZ
Number of subjects: 50
Study 24429091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric hydration
Number of subjects: 759
Study 24429091 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 759
Study 22403981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral hearing device (SoundBite)
Number of subjects: 22
Study 19843034 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain-Encoded MRI
Number of subjects: 69
Study 16393740 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced gender‐specific and culturally specific HIV intervention
Number of subjects: 333
Study 16393740 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation intervention arm
Number of subjects: 333
Study 16393740 — intervention group
Group type: COMPARATOR
Intervention: NIDA standard condition
Number of subjects: 333
Study 15289187 — intervention group
Group type: EXPERIMENTAL
Intervention: CPU care
Number of subjects: 972
Study 15289187 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 972
Study 15289187 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 972
Study 11345378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pharmacologic treatment with flecainide (group A, n = 23)
Number of subjects: 71
Study 11345378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid treatment (catheter ablation of the inferior vena cava‐tricuspid annulus isthmus, plus oral flecainide) (group B, n = 24)
Number of subjects: 71
Study 11345378 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of the isthmus only (group C, n = 24)
Number of subjects: 71
Study 11345378 — intervention group
Group type: COMPARATOR
Intervention: Control group (group D, n = 37)
Number of subjects: 71
Study 9230767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inhalation of l-menthol
Number of subjects: 11
Study 9230767 — intervention group
Group type: COMPARATOR
Intervention: Nasal inhalation of strawberry-flavored air
Number of subjects: 11
Study 8061442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at standard dose (0.1 mmol/kg)
Number of subjects: 289
Study 8061442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at higher dose (0.3 mmol/kg)
Number of subjects: 289
Study 8061442 — intervention group
Group type: COMPARATOR
Intervention: Both doses of gadodiamide injection
Number of subjects: 289
Study 3377272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 1200 mg daily in addition to basic therapy (antihypertensives, antidiabetic drugs, etc)
Number of subjects: 100
Study 3377272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pentoxifylline or other hemorheologic medication)
Number of subjects: 100
Study 4919118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrizym
Number of subjects: 12